The antibodies nivolumab and pembrolizumab bind to the programmed death 1 (PD-1) protein, a cell receptor, thus blocking binding by the ligand PD-L1 and preventing immunosuppression by the tumor cells. This evidence concerns the gene CD274 and neoplasm.